Alimera Sciences Limited has received pricing and reimbursement approval for Iluvien from Comité Economique des Produits de Santé in France, Alimera Sciences announced in a press release.
The sustained-release fluocinolone acetonide intravitreal implant is indicated in the European Union to treat vision impairment associated with chronic diabetic macular edema that is insufficiently responsive to available therapies.
“France is a very strong intraocular steroid market, and we believe the availability of an innovative product to uniquely treat the disease consistently every day to reduce the recurrence of edema will be welcomed by retinal specialists and patients,” Rick Eiswirth, Alimera’s president and CEO, said in the release.
Iluvien will be distributed in France by Horus Pharma, which will also handle promotion, marketing and commercial activities for the implant.
‘‘The knowledge and expertise of Horus regarding pricing and reimbursement has now made Iluvien and its continuous microdosing delivery available to patients in France and completes reimbursement in the five biggest European countries,’’ Eiswirth said in the release.